Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Minia University
Modality
protein_peptide
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05349448CT.gov Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study | — | Unknown | — | — | — |
NCT05344495CT.gov Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome: | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuralgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hyaluronidase (this asset) | Minia University | Early P1 | C · 39 |
| Dexmedetomidine | Universidad Juárez Autónoma de Tabasco | P4 | BBB |
| Midazolam | Minia University | P4 | BBB |
| Lidocaine | Ataturk University | P4 | BBB |
| Marcaine | Medipol University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Margaux M. Salas, PhD | P4 | BBB |
| Capsaicin | University Hospital, Clermont-Ferrand | P4 | BBB |
| Pregabalin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P4 | BBB |
| Nabilone | Eldon Loh, MD | P4 | BBB |
+42 more in the Neuralgia cohort
Other indications for Hyaluronidase
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
| Diffuse Large B-Cell Lymphoma | — | P2 | CCC · 51 |
| Chronic Pain Syndrome | — | Early P1 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hyaluronidase in Neuralgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hyaluronidase-neuralgia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →